CYP2C19 and depressive disorder: Compared with the higher conversion rates of CYP1A2 and CYP2C19 in the model group, the administration group of the Shuganjieyu capsule can inhibit the increase of liver microsomal CYP1A2 and CYP2C19 activities in CUMS depression rats.